218 related articles for article (PubMed ID: 31822956)
1. Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison.
Yu SY; Lee B; McGuire TM; Lee HJ; Hollingworth SA
Eur J Clin Pharmacol; 2020 Apr; 76(4):547-555. PubMed ID: 31822956
[TBL] [Abstract][Full Text] [Related]
2. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
3. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications.
Zhu LL; Xu LC; Chen Y; Zhou Q; Zeng S
World J Gastroenterol; 2012 Jun; 18(24):3167-72. PubMed ID: 22791953
[TBL] [Abstract][Full Text] [Related]
4. Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.
Tett SE; Sketris I; Cooke C; van Zanten SV; Barozzi N
Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):735-43. PubMed ID: 23559528
[TBL] [Abstract][Full Text] [Related]
5. Marked increase in proton pump inhibitors use in Australia.
Hollingworth S; Duncan EL; Martin JH
Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1019-24. PubMed ID: 20623646
[TBL] [Abstract][Full Text] [Related]
6. Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants: a national survey.
Bell JC; Schneuer FJ; Harrison C; Trevena L; Hiscock H; Elshaug AG; Nassar N
Arch Dis Child; 2018 Jul; 103(7):660-664. PubMed ID: 29472195
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
Barkun AN; Adam V; Martel M; Bardou M
Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
[TBL] [Abstract][Full Text] [Related]
8. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
Song TJ; Kim J
PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of proton pump inhibitors anti-ulcer drugs use in the Araba district primary care area].
Martínez Gorostiaga J; Echevarría Orella E; Calvo Hernáez B
Rev Esp Salud Publica; 2018 Aug; 92():. PubMed ID: 30100604
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
11. The Australian rise of esomeprazole-was expenditure on samples a contributor?
Kyle GJ; Nissen LM; Tett SE
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):62-8. PubMed ID: 19111014
[TBL] [Abstract][Full Text] [Related]
12. Overview of pharmacologic agents for acid suppression in critically ill patients.
Welage LS
Am J Health Syst Pharm; 2005 May; 62(10 Suppl 2):S4-S10. PubMed ID: 15905600
[TBL] [Abstract][Full Text] [Related]
13. Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan.
Tsumura H; Tamura I; Tanaka H; Chinzei R; Ishida T; Masuda A; Shiomi H; Morita Y; Yoshida M; Kutsumi H; Inokuchi H; Doita M; Kurosaka M; Azuma T
Intern Med; 2007; 46(13):927-31. PubMed ID: 17603228
[TBL] [Abstract][Full Text] [Related]
14. Gastric acid suppressants--too much of a good thing?
Logan IC; Sumukadas D; Witham MD
Age Ageing; 2010 Jul; 39(4):410-1. PubMed ID: 20507846
[No Abstract] [Full Text] [Related]
15. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
16. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
Fraeyman J; Van Hal G; Godman B; Beutels P
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
[TBL] [Abstract][Full Text] [Related]
17. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
18. Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia.
Wu J; Dickinson S; Elgebaly Z; Blogg S; Heaney A; Soo Y; Daniels B; Weekes L
BMC Fam Pract; 2020 May; 21(1):85. PubMed ID: 32386520
[TBL] [Abstract][Full Text] [Related]
19. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
20. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
